title: Preoperative Plasma Aldosterone Levels and Postoperative Atrial Fibrillation Occurrence Following Cardiac Surgery: A Review of Literature and Design of the ALDO-POAF Study (ALDOsterone for Prediction of Post-Operative Atrial Fibrillation).
abstract: Post-operative atrial fibrillation (POAF) is a major and frequent complication occurring after cardiac surgery, contributing to prolonged intensive care and hospital stays and is associated with several cardiovascular complications. The exact mechanisms and signaling pathways involved in the development of POAF seem to be multifactorial and remain to date incompletely understood. β-blockers and amiodarone are the first line preventive drugs but are partially effective and near 30% of POAF resist to these strategies.
  
  
  
  In this work, we review the current knowledge about pathophysiological POAF mechanisms and preventive pharmacological strategies. We also discuss the rational for the use of pre-operative plasma aldosterone and galectin-3 (Gal-3) levels as predictive biomarkers of POAF and the potential role of aldosterone antagonists in the POAF preventive strategy.
  
  
  
  POAF is a major complication occurring after cardiac surgery. In this context, there is some evidence indicating that renin-angiotensin-aldosterone system and Gal-3 could be very useful predictive biomarkers of POAF and potentially interesting therapeutic target to prevent POAF occurrence. We present the rationale and the design of the ALDO-POAF trial (ALDOsterone for prediction of Post- Operative Atrial Fibrillation, NCT 02814903).
authors.forename: Mathieu
authors.initials: M
authors.lastname: Chequel
authors.forename: Pierre
authors.initials: P
authors.lastname: Ollitrault
authors.forename: Eric
authors.initials: E
authors.lastname: Saloux
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Parienti
authors.forename: Marc-Olivier
authors.initials: MO
authors.lastname: Fischer
authors.forename: Julien
authors.initials: J
authors.lastname: Desgué
authors.forename: Stéphane
authors.initials: S
authors.lastname: Allouche
authors.forename: Paul
authors.initials: P
authors.lastname: Milliez
authors.affiliation: Department of Pharmacology, CHU de Caen, Avenue de la côte de nacre, 14000 Caen, France. alexandre-j@chu-caen.fr.
authors.forename: Joachim
authors.initials: J
authors.lastname: Alexandre
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000450:Aldosterone / Q000097:blood*; D000638:Amiodarone / Q000008:administration & dosage; D001281:Atrial Fibrillation / Q000209:etiology* / Q000517:prevention & control; D015415:Biomarkers / Q000097:blood; D006348:Cardiac Surgical Procedures / Q000009:adverse effects* / Q000379:methods; D037502:Galectin 3 / Q000097:blood; D006801:Humans; D011183:Postoperative Complications / Q000097:blood / Q000517:prevention & control; D057234:Preoperative Period; D012107:Research Design
chemical_list: D000319:Adrenergic beta-Antagonists; D015415:Biomarkers; D037502:Galectin 3; D000450:Aldosterone; D000638:Amiodarone